DFMO treatment in neuroblastoma cell lines inhibited proliferation, and when extended to in vivo studies using the TH-MYCN transgenic mouse, DFMO treatment from birth increased tumor latency and overall survival (Hogarty et al., 2008). This evidence concerns the gene MYCN and neoplasm.